These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34588761)

  • 1. A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease.
    McMullin D; Clark D; Cavanagh B; Karpecki P; Brady TC
    Clin Ophthalmol; 2021; 15():3889-3900. PubMed ID: 34588761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease.
    Clark D; Sheppard J; Brady TC
    J Ocul Pharmacol Ther; 2021 May; 37(4):193-199. PubMed ID: 33450164
    [No Abstract]   [Full Text] [Related]  

  • 3. Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis.
    Li JX; Tsai YY; Lai CT; Li YL; Wu YH; Chiang CC
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease.
    Nichols KK; Donnenfeld ED; Karpecki PM; Hovanesian JA; Raychaudhuri A; Shojaei A; Zhang S
    Eur J Ophthalmol; 2019 Jul; 29(4):394-401. PubMed ID: 30112930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
    Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
    Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
    Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
    Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial.
    Nichols KK; Holland E; Toyos MM; Peace JH; Majmudar P; Raychaudhuri A; Hamdani M; Roy M; Shojaei A
    Clin Ophthalmol; 2018; 12():263-270. PubMed ID: 29440868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Onset and Broad Activity of Reproxalap in a Randomized, Double-Masked, Vehicle-Controlled Phase 2b Trial in Dry Eye Disease.
    Clark D; Tauber J; Sheppard J; Brady TC
    Am J Ophthalmol; 2021 Jun; 226():22-31. PubMed ID: 33529588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.
    Donnenfeld ED; Karpecki PM; Majmudar PA; Nichols KK; Raychaudhuri A; Roy M; Semba CP
    Cornea; 2016 Jun; 35(6):741-8. PubMed ID: 27055211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial.
    Cavanagh B; Gomes PJ; Starr CE; Nichols KK; Brady TC
    Ophthalmol Ther; 2022 Aug; 11(4):1449-1461. PubMed ID: 35585427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety, and tolerability of lifitegrast 5% eye drops: A randomized, double-blind, active-controlled trial in Indian patients with dry eye disease.
    Sharma N; Basu S; Shetty R; Kumar P; Mondal A; Babu PS; Srivastava R; Pande RA; Karat S; Desai HP; Manjula S; Kumar MK
    Indian J Ophthalmol; 2025 Jan; 73(1):88-94. PubMed ID: 39141509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Phase 2 Trial of Reproxalap, a Novel Reactive Aldehyde Species Inhibitor, in Patients with Noninfectious Anterior Uveitis: Model for Corticosteroid Replacement.
    Mandell KJ; Clark D; Chu DS; Foster CS; Sheppard J; Brady TC
    J Ocul Pharmacol Ther; 2020 Dec; 36(10):732-739. PubMed ID: 32955967
    [No Abstract]   [Full Text] [Related]  

  • 14. Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra
    Hovanesian JA; Nichols KK; Jackson M; Katz J; Chan A; Glassberg MB; Sloesen B; Korves C; Nguyen C; Syntosi A
    Clin Ophthalmol; 2021; 15():1041-1054. PubMed ID: 33727786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial.
    Clark D; Cavanagh B; Shields AL; Karpecki P; Sheppard J; Brady TC
    Am J Ophthalmol; 2021 Oct; 230():60-67. PubMed ID: 33945820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease.
    Semba CP; Gadek TR
    Clin Ophthalmol; 2016; 10():1083-94. PubMed ID: 27354762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Phase 3 INVIGORATE Trial of Reproxalap in Patients with Seasonal Allergic Conjunctivitis.
    Starr CE; Nichols KK; Lang JR; Brady TC
    Clin Ophthalmol; 2023; 17():3867-3875. PubMed ID: 38105911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs.
    Chung JK; Spencer E; Hunt M; McCauley T; Welty D
    J Ocul Pharmacol Ther; 2018; 34(1-2):224-232. PubMed ID: 29267138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy.
    Godin MR; Gupta PK
    Clin Ophthalmol; 2017; 11():951-957. PubMed ID: 28579745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lifitegrast for the treatment of dry eye disease in adults.
    Donnenfeld ED; Perry HD; Nattis AS; Rosenberg ED
    Expert Opin Pharmacother; 2017 Oct; 18(14):1517-1524. PubMed ID: 28841079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.